<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455572</url>
  </required_header>
  <id_info>
    <org_study_id>107240</org_study_id>
    <nct_id>NCT00455572</nct_id>
  </id_info>
  <brief_title>Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer</brief_title>
  <official_title>Cancer Immunotherapeutic GSK1572932A as Adjuvant Therapy for Patients With MAGE-A3-positive Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to find out how successfully non-small-cell lung cancer&#xD;
      patients are able to give an immune response to injections of the immunotherapeutic product&#xD;
      GSK1572932A, and to find out more about the safety of this treatment. A course of eight&#xD;
      injections will be administered over 21 weeks; including screening for suitability and all&#xD;
      tests, the duration of the study for a patient will be 30-35 weeks. During this period&#xD;
      various tests will be performed, including physical examinations and blood tests. The&#xD;
      Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open, four-arm, parallel-group study, to be conducted at approximately 20 centers&#xD;
      in Europe and Canada. All patients will receive the same immunotherapeutic treatment with&#xD;
      GSK1572932A, but they will be recruited into four cohorts according to the details of their&#xD;
      disease. Cohort 1: Patients with resected stage IB, II or IIIA tumors who are due for&#xD;
      standard chemotherapy with cisplatin and vinorelbine. These patients will receive chemo-and&#xD;
      immunotherapy in parallel. Cohort 2: Patients with resected stage IB, II or IIIA tumors who&#xD;
      are due for standard chemotherapy with cisplatin and vinorelbine. These patients will first&#xD;
      receive chemotherapy and then immunotherapy.&#xD;
&#xD;
      Cohort 3: Patients with resected stage IB, II or IIIA tumors who are not due for&#xD;
      chemotherapy. These patients will receive immunotherapy only. Cohort 4: Patients with&#xD;
      unresectable stage III tumors, following standard chemotherapy and/or radiotherapy. These&#xD;
      patients will receive immunotherapy only. Immunotherapeutic treatment will comprise eight&#xD;
      doses of GSK1572932A. Doses will be administered at three-week intervals; in Cohort 1 this&#xD;
      may be adapted to fit in with the patient's chemotherapy. During the study, adjuvant&#xD;
      radiotherapy is allowed in Cohorts 1, 2 and 3 for patients in stage III only and is&#xD;
      prohibited in Cohort 4. Chemotherapy during the study is allowed in Cohort 1 only as&#xD;
      described above, and is prohibited in Cohorts 2-4. The total maximum duration of the study&#xD;
      for a patient will be 30-35 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study early termination was due to slow recruitment and difficulties at achieving the required&#xD;
    enrolment for the study.&#xD;
  </why_stopped>
  <start_date type="Actual">May 11, 2007</start_date>
  <completion_date type="Actual">August 8, 2013</completion_date>
  <primary_completion_date type="Actual">August 4, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The anti-MAGE-A3 seroconversion</measure>
    <time_frame>After the fourth dose of ASCI and at the end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The anti-protein D seroconversion</measure>
    <time_frame>After the fourth dose of ASCI and at the end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The anti-CpG seroconversion</measure>
    <time_frame>After the fourth dose of ASCI and at the end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The MAGE-A3 cellular (T cell) response</measure>
    <time_frame>After the fourth dose of ASCI and at the end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse events, including abnormal hematological and biochemical laboratory values</measure>
    <time_frame>During the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events</measure>
    <time_frame>During the study</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Lung Cancer, Non-Small Cell</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will receive chemo-and immunotherapy in parallel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will first receive chemotherapy and then immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with resected stage IB, II or IIIA tumors who are not due for chemotherapy. These patients will receive immunotherapy only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with unresectable stage III tumors, following standard chemotherapy and/or radiotherapy. These patients will receive immunotherapy only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunotherapeutic GSK1572932A</intervention_name>
    <description>Intramuscular injection, 8 doses</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (CDDP)</intervention_name>
    <description>Four cycles with doses based on patient's body surface area, intravenous administration</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Four cycles with doses based on patient's body surface area , intravenous administration</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Regimen will be based upon the site's own standard procedures</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained,&#xD;
&#xD;
          -  Aged 18 or more,&#xD;
&#xD;
          -  Pathologically proven stage IB, II or III NSCLC,&#xD;
&#xD;
          -  Tumor expresses MAGE-A3,&#xD;
&#xD;
          -  Free of distant metastasis,&#xD;
&#xD;
          -  For Cohort 1, all of the following:&#xD;
&#xD;
               1. Completely resected stage IB, II or IIIA NSCLC,&#xD;
&#xD;
               2. Anatomical tumor resection, involving at least a lobectomy, and nodal sampling as&#xD;
                  per center standard&#xD;
&#xD;
               3. ECOG performance status = 0 or 1&#xD;
&#xD;
               4. Due to receive adjuvant chemotherapy as permitted in the protocol&#xD;
&#xD;
               5. Not received, not receiving, and not due to receive adjuvant radiotherapy (except&#xD;
                  stage III patients)&#xD;
&#xD;
               6. First administration of chemotherapy can be scheduled within 4-12 weeks after&#xD;
                  surgery&#xD;
&#xD;
          -  For Cohort 2, all of the following:&#xD;
&#xD;
               1. Resected stage IB, II or IIIA NSCLC,&#xD;
&#xD;
               2. Anatomical tumor resection, involving at least a lobectomy, and nodal sampling as&#xD;
                  per center standard&#xD;
&#xD;
               3. ECOG PS = 0 or 1&#xD;
&#xD;
               4. Due to receive, or receiving, adjuvant chemotherapy as permitted in the protocol&#xD;
&#xD;
               5. Not received, not receiving, and not due to receive, adjuvant radiotherapy&#xD;
                  (except stage III patients)&#xD;
&#xD;
               6. First administration of ASCI treatment can be scheduled within 2-4 weeks after&#xD;
                  the last administration of chemotherapy&#xD;
&#xD;
               7. Received at least 2 cycles of standard chemotherapy before ASCI treatment is&#xD;
                  initiated, whereafter no further chemotherapy is planned&#xD;
&#xD;
          -  For Cohort 3, all of the following:&#xD;
&#xD;
               1. Resected stage IB, II or IIIA NSCLC&#xD;
&#xD;
               2. Anatomical tumor resection, involving at least a lobectomy, and nodal sampling as&#xD;
                  per center standard&#xD;
&#xD;
               3. ECOG PS = 0 or 1 or 2&#xD;
&#xD;
               4. Not received, not receiving, and not due to receive, adjuvant chemotherapy&#xD;
&#xD;
               5. Not received, not receiving, and not due to receive, adjuvant radiotherapy (this&#xD;
                  does not apply to patients in stage III)&#xD;
&#xD;
               6. First administration of ASCI treatment can be scheduled within 4-8 weeks after&#xD;
                  surgery&#xD;
&#xD;
          -  For Cohort 4, all of the following:&#xD;
&#xD;
               1. Unresectable stage III NSCLC&#xD;
&#xD;
               2. ECOG PS = 0 or 1 or 2&#xD;
&#xD;
               3. Due to receive, or receiving, chemo- and radiotherapy according to institution&#xD;
                  standard&#xD;
&#xD;
               4. Received at least 2 cycles of standard chemotherapy before the initiation of ASCI&#xD;
                  treatment, whereafter no further chemo-/radiotherapy is planned&#xD;
&#xD;
               5. Stable disease or objective response (confirmed by CT scan) after standard&#xD;
                  chemo-/radiotherapy&#xD;
&#xD;
               6. Administration of ASCI treatment can be scheduled within 2-6 weeks after the last&#xD;
                  administration of chemo-/radiotherapy&#xD;
&#xD;
          -  Laboratory criteria: adequate bone-marrow reserve, adequate renal function, adequate&#xD;
             hepatic function.&#xD;
&#xD;
          -  For females: EITHER not of child-bearing potential, OR sexually abstinent, OR negative&#xD;
             urine pregnancy test + use of adequate contraceptive precautions from 30 days before&#xD;
             first study treatment till 2 months after completion of study treatment course&#xD;
&#xD;
          -  In the view of the investigator, the patient can and will comply with the requirements&#xD;
             of the protocol&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Previous or concomitant other malignancies, except if effectively treated and&#xD;
             considered by the investigator highly likely to have been cured&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  History of anaphylaxis or severe allergic reaction&#xD;
&#xD;
          -  Concurrent severe medical problems, unrelated to the malignancy, limiting full&#xD;
             compliance with the study or exposing the patient to unacceptable risk&#xD;
&#xD;
          -  Psychiatric or addictive disorders compromising the ability to give informed consent,&#xD;
             or to comply with the trial procedures&#xD;
&#xD;
          -  HIV-positive&#xD;
&#xD;
          -  Require treatment with systemic corticosteroids, or other immunosuppressive agents&#xD;
&#xD;
          -  Need home oxygenation&#xD;
&#xD;
          -  Received or plan to receive investigational or non-registered product other than the&#xD;
             study medication from 30 days before first dose of study medication and during whole&#xD;
             study period&#xD;
&#xD;
          -  History of chronic alcohol consumption and/or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Li√®ge</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hemer</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grosshansdorf</city>
        <state>Schleswig-Holstein</state>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Berka</city>
        <state>Thueringen</state>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Udine</city>
        <state>Friuli-Venezia-Giulia</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wythenshawe</city>
        <state>Greater Manchester</state>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bebington, Wirral</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>April 2, 2007</study_first_submitted>
  <study_first_submitted_qc>April 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2007</study_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapeutic</keyword>
  <keyword>Adjuvant cancer therapy</keyword>
  <keyword>Non-small-cell lung cancer</keyword>
  <keyword>ASCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>107240</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107240</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107240</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107240</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107240</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107240</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107240</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

